Oliver Rosen

Oliver Rosen has an extensive work experience in the biotechnology and pharmaceutical industries. Oliver is currently the Chief Medical Officer at Akamis Bio and a Member of the Advisory Board at Kernal Biologics, starting in 2023. In 2022, they served as the President and Chief Medical Officer at DynamiCure Biotechnology, where they successfully filed INDs for two anti-CD93 mAbs and advanced the discovery pipeline. Prior to DynamiCure, they were the Chief Medical Officer at SQZ Biotechnologies from 2019 to 2021. Oliver also held the position of Chief Medical Officer at Deciphera Pharmaceuticals from 2014 to 2018.

Before joining Deciphera, Oliver Rosen gained experience in medical affairs and product launch preparation at Millennium Pharmaceuticals, where they served as the Vice President of Global Medical Affairs and Senior Medical Director from 2009 to 2014. Oliver also worked at Genentech as a Senior Medical Director and Medical Director from 2006 to 2009, and at Amgen Inc. as an Associate Director of Medical Affairs from 2004 to 2006. Prior to their industry roles, they worked as a Clinical Scientist at Hoffmann-La Roche in 2003.

In addition to their industry experience, Oliver Rosen has demonstrated a commitment to community service. Oliver was a Member of the Board of Directors for Community Servings, an organization that provides nutritious meals to patients with chronic diseases and offers job training for healthcare workers and nutrition counseling from 2015 to 2018. Oliver also served as a Member of the Board of Mentors at Community Servings from 2018 and continues to contribute to the organization.

Overall, Oliver Rosen's work experience showcases their leadership and expertise in the biotechnology and pharmaceutical fields, as well as their dedication to serving the community.

Oliver Rosen obtained their M.D. degree from the University of Cologne, where they studied at the Medical School from 1984 to 1991. During their time at the University of Cologne, they also completed a thesis in Electrophysiological Pharmacology from 1988 to 1991. Oliver then pursued further studies in Molecular Biology at the University of Hamburg from 1991 to 1994. To specialize in Hematology & Oncology, they attended Humboldt-Universität zu Berlin from 1995 to 2000.